The nuclear factor-kappaB (NF-κB) signaling pathway is considered as a potential therapeutic target in cancer therapy. It has been well established that transcription factor NF-κB is involved in regulating physiological and pathological events including inflammation, immune response and differentiation. Increasing evidences suggest that deregulated NF-κB signaling can enhance cancer cell proliferation, metastasis and also mediate radio-as well as chemo-resistance. On the contrary, non-coding RNAs (ncRNAs) have been found to modulate NF-κB signaling pathway under different settings. MicroRNAs (miRNAs) can dually inhibit/induce NF-κB signaling thereby affecting the growth and migration of cancer cells. Furthermore, the response of cancer cells to radiotherapy and chemotherapy may also be regulated by miRNAs. Regulation of NF-κB by miRNAs may be mediated via binding to 3-UTR region. Interestingly, anti-tumor compounds can increase the expression of tumor-suppressor miRNAs in inhibiting NF-κB activation and the progression of cancers. Long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) can also effectively modulate NF-κB signaling thus affecting tumorigenesis. Noteworthy, several studies demonstrate that lncRNAs and circRNAs can affect miRNAs in targeting NF-κB activate. They can act as competing endogenous RNA (ceRNA) thereby reducing miRNA expression to induce NF-κB activation that can enhance cancer progression and malignancy.Copyright © 2021. Published by Elsevier B.V.
About The Expert
Sepideh Mirzaei
Ali Zarrabi
Farid Hashemi
Amirhossein Zabolian
Hossein Saleki
Adnan Ranjbar
Seyed Hesam Seyed Saleh
Morteza Bagherian
Seyed Omid Sharifzadeh
Kiavash Hushmandi
Alena Liskova
Peter Kubatka
Pooyan Makvandi
Vinay Tergaonkar
Alan Prem Kumar
Milad Ashrafizadeh
Gautam Sethi
References
PubMed